OVARIAN CANCER and US: The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

OVARIAN CANCER and US

An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.

“Not everything that can be counted counts and not everything that counts can be counted.”

Albert Einstein

Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼

Wednesday, August 22, 2012

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

http://www.ncbi.nlm.nih.gov/m/pubmed/21892704/

Sent from my iPhone

OvarianCancerandUs

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.

View web version

Sandi Pniauskas Ovarian Cancer and Us

OvarianCancerandUs

View my complete profile

Powered by Blogger.